About 2022 - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

The 2022 Annual
PRIMO Meeting Agenda


The PRIMO meeting Co-Chairs, Steering Committee, and Education Committee are working hard to curate an agenda to meet the educational needs of all attendees and will focus on the following key areas:

  • Practical considerations of applying biomarkers and targeted therapy
  • Integration of immunotherapy, with a focus on novel management approaches
  • Patient selection, as well as timing and sequencing of therapy
  • Dealing with important trends, such as big data and defining value in cancer care
12:00 PM – 7:00 PM
6:30 PM – 8:00 PM
Welcome reception at the Grand Staircase at the Hilton Waikoloa Village
Join us in honoring the 2022 Women in Oncology Award winners

6:30 AM – 3:00 PM
Exhibits open
6:30 AM – 7:00 AM
Rise & Shine Booster
7:00 AM – 7:05 AM
Meeting Welcome
7:05 AM – 7:10 AM
Program Overview
Hematologic Malignancies - Julie M. Vose, MD, MBA / Sagar Lonial MD, FACP
7:10 AM – 7:30 AM
Update on Novel Therapies for Non-Hodgkin Lymphoma
7:30 AM – 7:50 AM
Relapsed and Refractory Multiple Myeloma: Choosing the Right Treatment
7:50 AM – 8:10 AM
Sequencing of Therapies for Chronic Lymphocytic Leukemia
8:10 AM – 8:30 AM
Acute Myelogenous Leukemia: Treatment Options
Product Theater
9:00 AM – 9:45 AM
Product Theater Breakfast: Showcase (Non-CME/CE)
9:45 AM – 10:00 AM
Visit Exhibits
Mjultidisciplinary Onocology Team - Jorge J. García, PharmD, MS, MHA, MBA, FACHE
10:00 AM – 10:20 AM
Physician Assistant Presentation: Immunotherapy Side Effects Management
10:20 AM – 10:40 AM
Pharmacist Presentation:
Biosimilars in Hematology and Oncology - Breaking Barriers
10:40 AM – 11:00 AM
Nurse Practitioner Presentation: Management of Patients at Risk for Hereditary Cancers
Product Theater
11:30 AM – 12:15 PM
Product Theater Lunch: Showcase (Non-CME/CE)
12:15 PM – 12:30 PM
Visit Exhibits
Gastrointestinal Malignancies - Rachna T. Shroff, MD, MS
12:30 PM – 12:50 PM
Changing the Landscape in Pancreatic/Biliary Cancers
12:50 PM – 1:10 PM
The Targeted and Immunotherapy Revolution in Upper GI Malignancies
1:10 PM – 1:35 PM
Q&A | Panel discussion
Product Theater
1:40 PM – 3:10 PM
Product Theater (Non-CME/CE)
Evening Reception*
5:30 PM – 7:00 PM
Sunset Mingle with Faculty and Industry (*by invite only)

6:30 AM – 3:00 PM
Exhibits open
6:30 AM – 7:00 AM
Rise & Shine Booster
7:00 AM – 7:05 AM
Welcome and Day 2 Program Overview
Melanoma and Skin Cancers - Shane Y. Morita, MD, MS, PhD, FACS
7:05 AM – 7:25 AM
Advanced Melanoma: Making Sense of the Data
7:25 AM – 7:35 AM
Advanced Melanoma: Making Sense of the Data Q & A
7:35 AM – 7:55 AM
Recent Advances and Historical Perspectives in Soft Tissue Sarcoma
7:55 AM – 8:05 AM
Recent Advances and Historical Perspectives in Soft Tissue Sarcoma Q & A
Product Theater
8:10 AM – 8:55 AM
Product Theater Breakfast: Showcase (Non-CME/CE)
8:55 AM – 9:10 AM
Visit Exhibits
Genitourinary Cancer – Sanjiv Agarwala
9:10 AM – 9:30 AM
Immunotherapy in Bladder Cancer – Current Status
9:30 AM – 9:55 AM
Current Update on Systemic Therapy for Advanced Prostate Cancer
9:55 AM – 10:10 AM
Q&A | Panel discussion
Special Lecture - Neoadjuvant Therapy - Sanjiv S. Agarwala, MD
10:10 AM – 10:30 AM
Neoadjuvant Therapy as a Paradigm Change for Cancer Treatment
10:30 AM – 10:35 AM
Neoadjuvant Therapy as a Paradigm Change for Cancer Treatment Q & A
Product Theater
10:40 AM – 11:25 AM
Product Theater Lunch: Showcase (Non-CME/CE)
11:25 AM – 11:40 AM
Desserts | Visit Exhibits
Lung/Head and Neck Cancer - Luis E. Raez, MD, FACP, FCCP
11:40 AM – 12:20 PM
Debate: Choosing Front Line Therapy for Non-Actionable NSCLC
11:40 AM - 12:00 PM Chemo/Immunotherapy Combinations
12:00 PM - 12:20 PM Immunotherapy alone or IO-IO combinations
12:20 PM – 12:40 PM
Updates on Targeted Therapy NSCLC (EGFR, ALK, ROS, RET and KRASg12c)
12:40 PM – 1:00 PM
Immunotherapy for Head and Neck Cancer
1:30 PM – 2:30 PM
Case Studies (Non-CME/CE)

6:30 AM – 11:00 AM
Exhibits open
6:30 AM – 7:50 AM
Rise & Shine Booster
7:00 AM – 7:15 AM
Enjoy PriMosas, Coffee with our VIP Industry Connection (Sponsor of the day)
7:15 AM – 7:20 AM
Welcome and Day 3 Program Overview
7:20 AM – 8:00 AM
Breast Tumor Board Session

Join forces with our breast KOLs and participate in an active discussion on the most interesting breast cases.

Breast Cancer - Hope S. Rugo, MD, FASCO
8:00 AM – 8:20 AM
Genomics for Early Stage Breast Cancer: Are Numbers the Key?
8:20 AM – 8:40 AM
New Directions for TNBC: Immunotherapy and Beyond
8:40 AM – 9:00 AM
Many Flavors: New Direction in the Treatment of HER2+ Breast Cancer
9:00 AM – 9:20 AM
Expanding Treatment Options for HR+ Breast Cancer
Product Theater
9:50 AM – 10:35 AM
Product Theater Breakfast: Showcase (Non-CME/CE)
10:35 AM – 10:50 AM
Visit Exhibits
Other Women’s Cancers - Hope S. Rugo, MD, FASCO
10:50 AM – 11:10 AM
Therapeutic Advances and Areas of Active Discovery in the Cervical Cancer Space
11:10 AM – 11:30 AM
Advances and Updates in the Treatment of Ovarian Cancer
11:30 AM – 11:50 AM
Complications of Anticancer Therapy: from the Genitourinary Symptoms of Menopause to Sexual Dysfunction
12:15 PM - 12:20 PM
Closing Remarks

We acknowledge commercial support from Taiho Oncology, Exelixis, Pfizer, AstraZeneca, and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.


Registration Type Early
01/01/2021 - 08/31/2021
09/01/2021 - 12/31/2021
01/01/2022 - 02/15/2022
Allied Health

For more information regarding travel mandates, please visit the following sites:
Also, be sure to check with your flight provider for additional information regarding travel to Hawaii.
*All conference attendees will be required to show proof of COVID vaccination.

Join your colleagues and explore key developments in cancer care over the past 12 months as well as the anticipated advances that you and your patients will likely see in the upcoming year.

Target Audience

This activity has been designed to meet the educational needs of Academic and Community Practitioners, as well as Registered Nurses and Advanced Practice Registered Nurses, Pharmacists and Physician Assistants from all oncology specialties, treating all disease sites involved in the care of patients with cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
  • Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
  • Identify patients who are appropriate candidates for targeted and immunologic therapies;
  • Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
  • Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.

PRIMO 2020
at a Glance

26 Conference Sponsors

THE PRACTICAL RECOMMENDATIONS IN IMMUNO AND MOLECULAR ONCOLOGY MEETING is a unique opportunity to receive CME/CE credits while staying ahead of the latest advances in immuno and molecular oncology.

The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.

Accredited by:

MEC Logo

Accreditation and Credit Statements

Jointly Accredited Provider Logo
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
IPCE Credit Logo
This activity was planned by and for the healthcare team, and learners will receive 13.5 Interprofessional Continuing Education (IPCE) credit for learning and change.


The Medical Educator Consortium designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


The Medical Educator Consortium designates this activity for 13.5 contact hours.


This Application-based activity has been approved for 13.5 contact hours (1.3 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-21-009-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Assistant

AAPA Cat1 CME logo
The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.


The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and the ACCME Standards for Integrity and Independence in Accredited Continuing Education. As a Joint Accreditation (JA) provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All persons that will be in a position to control the content of the CME/CE Activity are required to disclose all relevant financial relationships, regardless of the amount, that they have had in the past 24 months with ineligible companies. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners. A Disclosure Index document outlining this information will be made available to participants prior to the educational activity. The source of all commercial support from ineligible companies will also be disclosed to learners prior to the beginning of the educational activity. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.